Delpazolid not checked

LigaChem Biosciences, Inc. · LCB01-0371

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.”In the company’s words, NCT04550832 on ClinicalTrials.gov
Tested for
Infections and Infestations, Pulmonary Tuberculosis, MRSA Bacteremia, Nontuberculous Mycobacterium Infection, Mycobacterium Abscessus Infection
Main trialPhase 2
“This trial is to describe the safety, tolerability and exposure-toxicity relationship of Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and Moxifloxacin, compared to standard-dose Bedaquiline, Delamanid and Moxifloxacin alone”In the company’s words, NCT04550832 on ClinicalTrials.gov
Other names
LCB01-0371

Other drugs for Pulmonary Tuberculosis

All 3 drugs for Pulmonary Tuberculosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Completed 4 Jan 2023 PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Phase 2Terminated 21 Feb 2024 A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
Phase 2Completed 15 Sep 2025 Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
Phase 1Completed 3 Aug 2020 A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace
Phase 1Completed 24 Jan 2021 Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Delpazolid

Following is part of Solo: you see every change to Delpazolid the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in